Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has …
A Raman, SR Jinkala, R Murugan… - International Journal of …, 2024 - journals.lww.com
Mantle cell lymphoma (MCL) constitutes 3%–10% of non-Hodgkin lymphoma and is characterized by t (11: 14)(q13; q32). The common presentation is generalized …
A Raman, S Jinkala, R Murugan… - … Journal of Applied & …, 2024 - search.ebscohost.com
Mantle cell lymphoma (MCL) constitutes 3%–10% of non-Hodgkin lymphoma and is characterized by t (11: 14)(q13; q32). The common presentation is generalized …
N Fukushima, T Mino, K Arihiro, T Ichinohe - Cureus, 2022 - ncbi.nlm.nih.gov
The neoplastic cells of mantle cell lymphoma (MCL) usually express CD5 and not CD10. However, cases of MCL with aberrant expression of CD10 have been seldom reported. A 71 …